In two separate studies, malaria researchers are exploring the potential of a long-acting injectable preventive compound and an approach from cancer treatments that could be used as a single-dose cure.

Medicines for Malaria Venture (MMV) and Quotient Sciences have begun the first clinical trial for their long-acting injectable (LAI) preventive compound for malaria.

The trial of MMV371, a derivative of atovaquone, will be conducted in healthy volunteers in Nottingham, UK.

MMV371 is already approved as part of atovaquone-proguanil (Malarone), a medicine widely used by travellers to malaria-endemic areas. It is being tested in an injectable form that could provide up to three months of protection with a single intramuscular dose.

The final injectable medicine will be a fixed-dose combination of MMV371 and a suitable partner drug – a strategy that reduces the likelihood of inducing resistant strains of malaria parasites. Another compound in MMV’s pipeline, MMV055, is a potential partner drug candidate and is expected to enter clinical development in 2025.

The new drug combination could also potentially clear asymptomatic malaria infections, a condition in which malaria parasites are present in the blood, but no symptoms appear.

Pending positive outcomes of the study, clinical trials in malaria-endemic countries are expected to begin in 2026.

“This trial brings us closer to our goal of offering a long-lasting, affordable solution for malaria prevention,” said Dr Stephan Chalon, Vice President of Experimental Medicine and Clinical Pharmacology at MMV.

According to the World Health Organization, in 2022, there were 249 million malaria cases and 608,000 deaths globally with sub-Saharan Africa bearing 95% of this burden.

Possible one-shot cure for malaria

Another team of researchers led by bioscientists at the University of Glasgow have adapted an approach from cancer treatments.

The drug works by permanently disabling a protein that Plasmodium falciparum, one of the mosquito-borne parasites which spreads malaria, uses to duplicate itself inside the human body.

In a paper published in the Journal of Medicinal Chemistry, they outline how the treatment could be more effective than current medications at all stages of malaria infection. It could also work as a single-dose treatment, the researchers say.

The new drug could help to overcome the growing problem of Plasmodium falciparum’s resistance to artemisinin, the current frontline treatment for malaria infections.

The new drug is a covalent kinase inhibitor that works by targeting a protein called PfCLK3, which plays a vital role in the parasite’s ability to splice RNA. By firmly attaching itself to the protein, the drug molecule essentially turns off the parasite’s method of replicating itself in the bloodstream, killing it before it can spread.

PhD student Skye Brettell, the paper’s first author, said: “Covalent kinase inhibitors are commonly used in oncology, but a frequent drawback is that, while targeting cancer proteins, these drugs often affect other proteins as well, leading to side effects. The molecule we’ve developed is much more focused on its target – it has a special chemical ‘grappling hook’ that ensures it sticks only to the PfCLK3 protein, which could help it treat malaria without causing unwanted effects in humans.”

Using mass spectrometry, the team showed that the drug was permanently binding to its targets. Further tests demonstrated that washing the parasites after six hours did not remove the effect of the drug.

In collaboration with Columbia University in New York, they also demonstrated that parasites were unable to develop resistance to the drug over time.

Diana Spencer, Senior Digital Content Editor, DDW